Gabapentin Capsule
Product Images NDC 16571-869

8 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 16571-869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)
Chemical structure of gabapentin showing its molecular configuration with a cyclohexane ring attached to two side chains including an amino group and a carboxyl group.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)
Line graph comparing mean pain scores over 8 weeks between placebo and gabapentin 3600 mg/day groups. The x-axis shows time in weeks including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin group shows a decreasing pain trend, placebo remains relatively stable.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)
Line graph depicting mean pain score over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including baseline and weeks 1 to 7, while the y-axis shows mean pain scores from 0 to 10. Two phases are noted: a 3-week dose titration period and a 4-week fixed dose period.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)
A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively, with noted statistical significance levels.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)
A scatter plot chart showing the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis for three studies labeled Study a, Study b, and Study c. Each study is represented with distinct square markers in black, gray, and white colors, respectively, and data points are annotated with letters a, b, or c.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 06)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 06)
Gabapentin Capsules, USP 100 mg packaging label by Rising Pharma Holdings, Inc. The label indicates a 30-capsule quantity and includes dosage instructions stating each capsule contains 100 mg of gabapentin. It notes storage conditions, dispensing requirements, and child-resistant packaging. Manufacturer and distributor details are listed, along with a barcode and a mention to dispense with the medication guide. The label clearly shows the product is Rx only.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 07)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 07)
Label for gabapentin Capsules, USP 300 mg, oral capsule dosage form, in a package of 30 capsules. The label includes instructions for pharmacists to dispense the accompanying Medication Guide, storage conditions, and a warning to keep out of reach of children. Labeler is Rising Pharma Holdings, Inc., with manufacturing for Rising Pharma Holdings, Inc. in New Jersey, and Graviti Pharmaceuticals Pvt. Ltd. in India. The label features the NDC 16571-868-03 and a barcode.*
FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 08)

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 08)
Gabapentin Capsules, USP 400 mg oral capsules label by Rising Pharma Holdings, Inc. The label states a package size of 30 capsules, with instructions to dispense the accompanying medication guide to patients. It includes storage details, tight container dispensing, and child-resistant closure information. Manufactured by Rising Pharma Holdings, Inc. in New Jersey, and Graviti Pharmaceuticals Pvt. Ltd. in India. The NDC is 16571-869-03.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.